Senores Pharmaceuticals inks agreement to acquire ANDA for Topiramate HCl 25, 50, 100, 200 mg tablets

05 May 2025 Evaluate

Senores Pharmaceuticals (SPL), through its wholly-owned subsidiary Senores Pharmaceuticals, Inc., USA (SPI), has signed agreement to acquire the USFDA-approved Abbreviated New Drug Application (ANDA) for Topiramate HCl 25, 50, 100 and 200 mg tablets (Topiramate) from Wockhardt.

Topiramate is indicated as a treatment of epilepsy and migraine. The market size of Topiramate Tablet in the USA was around $111.47 million (MAT December 2024) as per IQVIA. The acquisition will be funded through the Initial Public Offer (IPO) proceeds raised by SPL. This is in line with objects of the IPO stated in the Red Herring Prospectus.

Senores Pharmaceuticals is global research driven pharmaceutical company engaged in developing and manufacturing a wide range of generic pharmaceutical products in the B2B segment predominantly for the Regulated Markets across various therapeutic areas and dosage forms. 

Senores Pharmaceutic Share Price

777.40 -6.85 (-0.87%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×